SCOTUS to weigh 'materiality proof' question in Amgen class action case
This article was originally published in Scrip
Executive Summary
The US Supreme Court on 11 June said it would hear an appeal from Amgen claiming a lower court erred when it said a group of investors could move forward with a securities fraud class-action lawsuit alleging the biotech giant downplayed the US FDA's safety concerns about Aranesp (darbepoetin alfa) and Epogen (epoetin alfa) and caused the firm's stock prices to be inflated.
You may also be interested in...
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Clinton's Drug Price Plan: Threat Or Flash In The Political Pan?
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.